Since joining the faculty in 2012, James Rains has taught two of Tech’s most critical classes for creating the next generation of biomedical engineers. “Intro to Biomedical Engineering Design” and the “Biomedical Engineering Capstone” courses are bookends on the student experience in the BME program, which has consistently ranked among the best in the nation. Meanwhile, Rains helps give students more real-world healthcare problems from clinicians and medical companies than any other BME department in the world. He constantly strives to find the best and most diverse projects for his students, including in 2018, a new collaboration with the world-renowned Mayo Clinic. His BME student teams consistently win top honors in innovation competitions and mentors and coaches Create-X student startups. For all of his tremendous efforts, he was named the 2019 Undergraduate Educator of the Year by Tech’s Center for Teaching and Learning.

Felipe trained as a biomedical engineer in his native Colombia before obtaining a PhD from the Biomedical Engineering department of Duke University. At Duke, working in the laboratory of Ashutosh Chilkoti, he focused on the engineering of genetically-encoded, self-assembling protein polymers. An important outcome of this PhD work was the elucidation of sequence rules to program the phase separation behavior of intrinsically disordered proteins (IDPs). Motivated by a newly acquired ability to engineer the phase behavior of IDPs, for his postdoctoral work he turned to their poorly-understood biology. To pursue skin as an outstanding biological system, Felipe joined the group of Elaine Fuchs at Rockefeller University. Felipe’s postdoctoral research led to the discovery that liquid-liquid phase separation drives the process of skin barrier formation. In 2020, he established the Quiroz Lab in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University, where he is currently an Assistant Professor. Felipe is the recipient of multiple research awards, including a Career Award at the Scientific Interface from the Burroughs Wellcome Fund and the NIH Director’s New Innovator Award.

Peng Qiu is a professor in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech School of Engineering and Emory University School of Medicine. 

His research interests are in the areas of bioinformatics and computational biology, focusing on machine learning, data integration, statistical signal processing, control systems and optimization. 

In particular, he is interested in developing machine learning methods to advance single-cell data science, with applications in characterizing cellular heterogeneity, identifying cancer biomarkers, understanding disease progression, reconstructing gene regulatory networks, etc.

H. Jerry Qi is a professor and the Woodruff Faculty Fellow in the George W. Woodruff School of Mechanical Engineering at Georgia Institute of Technology. He received his bachelor degrees (dual degree), master and Ph.D. degree from Tsinghua University (Beijing, China) and a ScD degree from Massachusetts Institute of Technology (Boston, MA, USA). After one year postdoc at MIT, he joined University of Colorado Boulder as an assistant professor in 2004, and was promoted to associate professor with tenure in 2010. He joined Georgia Tech in 2014 as an associate professor with tenure and was promoted to a full professor in 2016. Qi is a recipient of NSF CAREER award (2007). He is a member of Board of Directors for the Society of Engineering Science. In 2015, he was elected to an ASME Fellow. The research in Qi's group is in the general area of soft active materials, with a focus on 1) 3D printing of soft active materials to enable 4D printing methods; and 2) recycling of thermosetting polymers. The material systems include: shape memory polymers, light activated polymers, vitrimers. On 3D printing, they developed a wide spectrum of 3D printing capability, including: multIMaTerial inkjet 3D printing, digit light process (DLP) 3D printing, direct ink write (DIW) 3D printing, and fused deposition modeling (FDM) 3D printing. These printers allow his group to develop new 3D printing materials to meet the different challenging requirements. For thermosetting polymer recycling, his group developed methods that allow 100% recycling carbon fiber reinforced composites and electronic packaging materials. Although his group develops different novel applications, his work also relies on the understanding and modeling of material structure and properties under environmental stimuli, such as temperature, light, etc, and during material processing, such as 3D printing. Constitutive model developments are typically based on the observations from experiments and are then integrated with finite element through user material subroutines so that these models can be used to solve complicated 3D multiphysics problems involving nonlinear mechanics. A notable example is their recent pioneer work on 4D printing, where soft active materials is integrated with 3D printing to enable shape change (or time in shape forming process). Recently, his developed a state-of-the-art hybrid 3D printing station, which allows his group to integrate different polymers and conduct inks into one system. Currently, his group is working on using this printing station for a variety of applications, including printed 3D electronics, printed soft robots, etc.

The research focus of Boris Prilutsky's laboratory is Neural Control and Biomechanics of Movement. They study how the nervous system controls hundreds of muscles and kinematic degrees of freedom of the body to produce purposeful motor behaviors and how the neural control of motor behaviors is affected by neural and musculoskeletal injuries.

Professor Mark R. Prausnitz is a Regents' Professor and the Love Family Professor in Chemical and Bimolecular Engineering in the School of Chemical & Bimolecular Engineering. He received his B.S. in 1988 from Stanford University and his Ph.D. in 1994 from the Massachusetts Institute of Technology. Professor Prausnitz and his colleagues carry out research on biophysical methods of drug delivery, which employ microneedles, ultrasound, lasers, electric fields, heat, convective forces and other physical means to control the transport of drugs, proteins, genes and vaccines into and within the body. A major area of focus involves the use of microneedle patches to apply vaccines to the skin in a painless, minimally invasive manner. In collaboration with Emory University, the Centers for Disease Control and Prevention, and other organizations, Professor Prausnitz's group is advancing microneedles from device design and fabrication through pharmaceutical formulation and pre-clinical animal studies through studies in human subjects. In addition to developing a self-administered influenza vaccine using microneedles, Professor Prausnitz is translating microneedle technology especially to make vaccination in developing countries more effective. The Prausnitz group has also developed hollow microneedles for injection into the skin and into the eye in collaboration with Emory University. In the skin, research focuses on insulin administration to human diabetic patients to increase onset of action by targeting insulin delivery to the skin. In the eye, hollow microneedles enable precise targeting of injection to the suprachoroidal space and other intraocular tissues for minimally invasive delivery to treat macular degeneration and other retinal diseases. Professor Prausnitz and colleagues also study novel mechanisms to deliver proteins, DNA and other molecules into cells. Cavitation bubble activity generated by ultrasound and by laser-excitation of carbon nanoparticles breaks open a small section of the cell membrane and thereby enables entry of molecules, which is useful for gene-based therapies and targeted drug delivery. In addition to research activities, Professor Prausnitz teaches an introductory course on engineering calculations, as well as two advanced courses on pharmaceuticals and technical communication, both of which he developed. He also serves the broader scientific and business communities as a frequent consultant, advisory board member and expert witness.

Faces of Research - Profile Article

Social aspects of MRI research and development in the United States, Britain, and India. Medical visualization through technologies such as MRI. Ethical and social dimensions of overseas stem cell therapy; with a particular focus on patients' narratives and how these narratives reflect negotiations around ethical, juridical, and social/personal concerns. Sociological investigation of misinformation and disinformation in relation to science, particularly in the context of the COVID-19 pandemic.

The goal of Christopher Porter's lab is to develop novel therapeutic strategies for leukemia through better understanding of molecular mechanisms of leukemogenesis and treatment resistance. We employ a wide variety of techniques, in vitro and in vivo, for discovery and validation of molecular vulnerabilities in cancer cells. For example, using a genome-scale shRNA screen, we identified WEE1 as a chemosensitizing target in acute myeloid leukemia (AML) cells. Subsequent studies funded by the NCI have validated this finding and supported the development of a clinical trials a WEE1 inhibitor in subjects with AML. More recently, we have discovered a novel function for the transcription factor ETV6 in regulating normal hematopoiesis and are testing whether and how Etv6 mutation promotes leukemogenesis using a new mouse model with a point mutation in Etv6. Another project in the lab is directed at understanding mechanisms of immune evasion during leukemogenesis, as well as enhancing immune cells’ response to leukemia cells.

Research in the Peroni laboratory focuses on the use of regenerative therapies ranging from cellular to blood derived products to treat musculoskeletal injuries, with a concentration on minimally invasive surgery such as laparoscopy, thoracoscopy and arthroscopy.

Current research project: The surgery, performed in May, is the second successful feline kidney transplant using feline adult stem cells performed at the hospital. “To the best of our knowledge, UGA is the only veterinary facility in the world to use adult stem cells in feline kidney transplantation,” said Dr. Chad Schmiedt, a board-certified small animal surgeon who heads UGA’s feline kidney transplant program.

The service laboratory is managed by research professionals Merrilee Thoresen and Jenny Mumaw, who is enrolled in the college’s doctor of veterinary medicine program and will graduate in 2016. The service is headed by Dr. John Peroni, a board-certified large animal surgeon and associate professor whose research focus includes stem cell therapeutics. Read More